Groups urge Fed Circ to rehear Biogen patent case

Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Biogen sues Teva over MS generic

18 March 2021 A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

Americas

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

More on this story

Americas

Biogen sues Teva over MS generic

18 March 2021 A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

Americas

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

More on this story

Americas

Biogen sues Teva over MS generic

18 March 2021 A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

Americas

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent